Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Uptake of New Therapies Pushes Treatment Paradigm Forward in Breast Cancer

April 22nd 2022

Recent developments across the breast cancer paradigm include the utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer, plus neoadjuvant treatment strategies in triple-negative breast cancer.

Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Bardia Reflects on Important Data in HER2+ Breast Cancer

April 21st 2022

Dr Bardia discusses data from DESTINY-Breast03, HER2CLIMB, and NALA, important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.

Personalized Medicine Evolves With CDK4/6 Inhibitors, Immunotherapy, and ADCs in Breast Cancer

April 21st 2022

Hadeel Assad, MD, discussed how CDK4/6 inhibitors have been implemented into practice and provided updates on key clinical trials in HER2-positive breast cancer and triple-negative breast cancer.

DESTINY-Breast03: T-DXd in HER2+ Metastatic Breast Cancer

April 21st 2022

Expert perspectives on the DESTINY-Breast03 trial, which compared T-DXd to T-DM1 in the setting of relapsed/refractory HER2+ metastatic breast cancer.

HER2+ mBC: Overview of Treatment Options and Sequencing

April 21st 2022

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.

Second Line T-DM1 Worsens Outcomes for HER2+ Breast Cancer in Real-World Study

April 19th 2022

Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer who progressed on pertuzumab and trastuzumab–based regimens.

Antibody-Drug Conjugates Are Carving Out Expanded Roles Throughout Breast Cancer

April 18th 2022

William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each space.

Patient Profile 1: Sequencing Therapies in HER2+ mBC

April 15th 2022

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

Patient Profile 1: Second-Line Therapy for HER2+ mBC

April 15th 2022

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

D'Abreo Addresses AEs in Metastatic Breast Cancer Care

April 14th 2022

Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

State of Science Summit- Breast Cancer: Chaired by Heather McArthur, MD

April 12th 2022

State of Science Summit- Breast Cancer: Chaired by Heather McArthur, MD

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Virginia Kaklamani, MD

April 12th 2022

Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBC

April 10th 2022

Melissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.

Biomarker-Directed Therapy Could Lead to Undertreatment of Nonclonal Recurrent DCIS

April 10th 2022

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

Recent Trial Data in HER2+ Metastatic Breast Cancer

April 8th 2022

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis

April 7th 2022

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

Dr. Sammons on Findings From the EMERALD Trial in ER+ Advanced or Metastatic Breast Cancer

April 6th 2022

Sarah Sammons, MD, discusses findings from the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.